ArticleGynecology and pelvic medicine2024
Management and prognosis of uterine sarcoma in elderly.
Article in Gynecology and pelvic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine sarcomas (US) are a rare heterogeneous group of malignancies which management remains challenging. Although elderly population is increasing, there is a lack of information about the special features of the disease in these patients. The objective of this study is to analyze the impact of age on the management and oncological outcomes of US. Methods: A retrospective multicenter study collected data from patients with US from January 2001 to December 2007. Data from patients diagnosed with adenosarcoma (AS), endometrial stromal sarcoma (ESS), leiomyosarcoma (LMS) and undifferentiated sarcoma were included and classified depending on age (cut-off point 70 years old). Overall survival (OS) and progression-free survival (PFS), as well as cancer-specific survival (CSS) were estimated using Kaplan-Meier method for both groups. Results: In total, 688 patients were included, of whom 122 (17.73%) were elderly. Median OS and CSS were 126 and 136 months for non-elderly patients and 115 months for both OS and CSS in elderly patients, respectively. No statistical differences in either OS or CSS were found between both groups. Incomplete cytoreduction and International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis were related to OS; however, no statistical differences were found between elderly and non-elderly patients in the stratified analysis when considering minimal residual disease (P=0.85) and gross residual disease (P=0.42). Conclusions: Age alone is not a contraindication for treatment with curative intention because. In addition, these elderly patients do not have a different CSS compared to younger patients so maximal surgical effort should be carried out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.